In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...

The team at GV manages some $10 billion that the tech giant has set aside for early-stage companies. Schenkein’s group ...

In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...

FDA decision-making may be reduced to a sequence of ‘make-a-deals’ with Trump, his FDA, or even political allies,” experts ...

To secure Cassidy’s decisive confirmation vote, Kennedy committed to maintaining the Centers for Disease Control and ...

The changes are the latest move by the federal health department, led by Robert F. Kennedy Jr., to sow doubt about childhood ...

The new report reveals that many of the authors and reviewers have been outspoken critics of gender-affirming care and belong ...

Abbott is buying Exact Sciences, the maker of tests designed to detect early cancers, in a $21 billion deal, a sign of ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

The list offers a view into the administrations plans for the CDC, an agency battered by job cuts and resignations.

Paradromics received regulatory approval to test its BCI device in a small clinical trial to assess its safety and efficacy.

Lots more details about the fallout from STAT’s John Wilkerson. Read more here.